中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 11
Nov.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(11): 2696-2700

Immunotherapy for acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2021.11.046
  • 1.

    Graduate School, Guangxi University of Chinese Medicine, Nanning 530001, China

  • 2.

    Department of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China

Research funding:

National Natural Science Foundation Project (81960841);

General Project of National Natural Science Foundation Project (82060848);

Guangxi Natural Science Fund Project (2018GXNSFAA281096);

Guangxi Natural Science Fund Project (2020JJA140273)

  • Received Date: 2021-03-28
  • Accepted Date: 2021-04-21
  • Published Date: 2021-11-20
    Abstract
  • Acute-on-chronic liver failure (ACLF) is a life-threatening disease with a high risk of multiple organ failure, sepsis, and death. ACLF activates innate and acquired immune responses in human body and thus leads to the progression of persistent systemic inflammatory response syndrome and multiple organ dysfunction, leading to the high mortality rate of this disease. Dysregulated immune response plays a key role in disease progression, and immunotherapy may help to target immune-mediated organ damage and inhibit the progression of liver failure. This article reviews the role and mechanism of drugs and means with a potential immune regulatory effect in ACLF, in order to provide a reference for immunotherapy for ACLF.

     

    • FullText(HTML)
  • loading
    • References(49)
  • [1]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [2]
    YIN S, WANG SJ, GU WY, et al. Risk of different precipitating events for progressing to acute-on-chronic liver failure in HBV-related cirrhotic patients[J]. J Dig Dis, 2017, 18(5): 292-301. DOI: 10.1111/1751-2980.12480.
    [3]
    SATSANGI S, DUSEJA A, SACHDEVA M, et al. Monocyte human leukocyte antigen - Antigen D related, neutrophil oxidative burst and cytokine analysis in patients of decompensated cirrhosis with and without acute-on chronic liver failure[J]. PLoS One, 2018, 13(7): e0200644. DOI: 10.1371/journal.pone.0200644.
    [4]
    CHEN P, WANG YY, CHEN C, et al. The immunological roles in acute-on-chronic liver failure: An update[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(5): 403-411. DOI: 10.1016/j.hbpd.2019.07.003.
    [5]
    SHUBHAM S, KUMAR D, ROOGE S, et al. Cellular and functional loss of liver endothelial cells correlates with poor hepatocyte regeneration in acute-on-chronic liver failure[J]. Hepatol Int, 2019, 13(6): 777-787. DOI: 10.1007/s12072-019-09983-y.
    [6]
    MA HC, SHI XL, REN HZ, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 to acute failing liver improves liver regeneration[J]. World J Gastroenterol, 2014, 20(40): 14884-14894. DOI: 10.3748/wjg.v20.i40.14884.
    [7]
    LEI Y, LIU Z, HAN Q, et al. G-CSF enhanced SDF-1 gradient between bone marrow and liver associated with mobilization of peripheral blood CD34+ cells in rats with acute liver failure[J]. Dig Dis Sci, 2010, 55(2): 285-291. DOI: 10.1007/s10620-009-0757-9.
    [8]
    KHANAM A, TREHANPATI N, GARG V, et al. Altered frequencies of dendritic cells and IFN-gamma-secreting T cells with granulocyte colony-stimulating factor (G-CSF) therapy in acute-on- chronic liver failure[J]. Liver Int, 2014, 34(4): 505-513. DOI: 10.1111/liv.12415.
    [9]
    SHARMA S, LAL SB, SACHDEVA M, et al. Role of granulocyte colony stimulating factor on the short-term outcome of children with acute on chronic liver failure[J]. J Clin Exp Hepatol, 2020, 10(3): 201-210. DOI: 10.1016/j.jceh.2019.10.001.
    [10]
    KARIMINEKOO S, MOVASSAGHPOUR A, RAHIMZADEH A, et al. Implications of mesenchymal stem cells in regenerative medicine[J]. Artif Cells Nanomed Biotechnol, 2016, 44(3): 749-757. DOI: 10.3109/21691401.2015.1129620.
    [11]
    LIN BL, CHEN JF, QIU WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial[J]. Hepatology, 2017, 66(1): 209-219. DOI: 10.1002/hep.29189.
    [12]
    MOUNAYAR M, KEFALOYIANNI E, SMITH B, et al. PI3kα and STAT1 interplay regulates human mesenchymal stem cell immune polarization[J]. Stem Cells, 2015, 33(6): 1892-1901. DOI: 10.1002/stem.1986.
    [13]
    JITSCHIN R, BÖTTCHER M, SAUL D, et al. Inflammation-induced glycolytic switch controls suppressivity of mesenchymal stem cells via STAT1 glycosylation[J]. Leukemia, 2019, 33(7): 1783-1796. DOI: 10.1038/s41375-018-0376-6.
    [14]
    LIEDER R, SIGURJONSSON OE. The effect of recombinant human interleukin-6 on osteogenic differentiation and YKL-40 expression in human, bone marrow-derived mesenchymal stem cells[J]. Biores Open Access, 2014, 3(1): 29-34. DOI: 10.1089/biores.2013.0035.
    [15]
    LIU Q, CHEN X, LIU C, et al. Mesenchymal stem cells alleviate experimental immune-mediated liver injury via chitinase 3-like protein 1-mediated T cell suppression[J]. Cell Death Dis, 2021, 12(3): 240. DOI: 10.1038/s41419-021-03524-y.
    [16]
    NEONG SF, ADEBAYO D, WONG F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 293-305. DOI: 10.1080/17474124.2018.1555469.
    [17]
    ARNAU-BARRÉS I, GVERRI-FERNÁNDEZ R, LUQUE S, et al. Serum albumin is a strong predictor of sepsis outcome in elderly patients[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(4): 743-746. DOI: 10.1007/s10096-019-03478-2.
    [18]
    O'Brien AJ, BRIEN AJ, FULLERTON JN, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2[J]. Nat Med, 2014, 20(5): 518-523. DOI: 10.1038/nm.3516.
    [19]
    CARACENI P, PAVESI M, BALDASSARRE M, et al. The use of human albumin in patients with cirrhosis: A European survey[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(6): 625-632. DOI: 10.1080/17474124.2018.1460203.
    [20]
    GIANNONE FA, DOMENICALI M, BALDASSARRE M, et al. Ischaemia-modified albumin: A marker of bacterial infection in hospitalized patients with cirrhosis[J]. Liver Int, 2015, 35(11): 2425-2432. DOI: 10.1111/liv.12860.
    [21]
    KUMAR PA, SUBRAMANIAN K. The role of ischemia modified albumin as a biomarker in patients with chronic liver disease[J]. J Clin Diagn Res, 2016, 10(3): BC09-12. DOI: 10.7860/JCDR/2016/17168.7399.
    [22]
    GAO L, WANG JF, XIANG M, et al. Expression of human glucocorticoid receptor in T lymphocytes in acute-on-chronic hepatitis B liver failure[J]. Dig Dis Sci, 2011, 56(9): 2605-2612. DOI: 10.1007/s10620-011-1656-4.
    [23]
    SHIMBA A, CUI G, TANI-ICHI S, et al. Glucocorticoids drive diurnal oscillations in T cell distribution and responses by inducing interleukin-7 receptor and CXCR4[J]. Immunity, 2018, 48(2): 286-298. e6. DOI: 10.1016/j.immuni.2018.01.004.
    [24]
    YU X, LAN P, HOU X, et al. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production[J]. J Hepatol, 2017, 66(4): 693-702. DOI: 10.1016/j.jhep.2016.12.018.
    [25]
    ZHAO Q, WU CS, FANG Y, et al. Glucocorticoid regulates NLRP3 in acute-on-chronic hepatitis B liver failure[J]. Int J Med Sci, 2019, 16(3): 461-469. DOI: 10.7150/ijms.30424.
    [26]
    ZHE-BIN W, KE W, MO ZS, et al. Early, short-term, low-dose glucocorticoid therapy effectively blocks progression of severe acute exacerbation of chronic hepatitis B to liver failure[J]. Clin Res Hepatol Gastroenterol, 2020 : 101505. DOI: 10.1016/j.clinre.2020.07.010.[Onlineaheadofprint]
    [27]
    HUANG C, YU KK, ZHENG JM, et al. Steroid treatment in patients with acute-on-chronic liver failure precipitated by hepatitis B: A 10-year cohort study in a university hospital in East China[J]. J Dig Dis, 2019, 20(1): 38-44. DOI: 10.1111/1751-2980.12691.
    [28]
    THURSZ MR, RICHARDSON P, ALLISON M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis[J]. N Engl J Med, 2015, 372(17): 1619-1628. DOI: 10.1056/NEJMoa1412278.
    [29]
    TAUBERT R, HARDTKE-WOLENSKI M, NOYAN F, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies[J]. J Hepatol, 2014, 61(5): 1106-1114. DOI: 10.1016/j.jhep.2014.05.034.
    [30]
    OO YH, WESTON CJ, LALOR PF, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver[J]. J Immunol, 2010, 184(6): 2886-2898. DOI: 10.4049/jimmunol.0901216.
    [31]
    FU XQ, CAI JY, LI MJ. Prednisone may rebuild the immunologic homeostasis: Alteration of Th17 and Treg cells in the lymphocytes from rats' spleens after treated with prednisone-containing serum[J]. Mol Genet Genomic Med, 2019, 7(7): e00800. DOI: 10.1002/mgg3.800.
    [32]
    KARKHANIS J, VERNA EC, CHANG MS, et al. Steroid use in acute liver failure[J]. Hepatology, 2014, 59(2): 612-621. DOI: 10.1002/hep.26678.
    [33]
    CHI JH, SEO GS, LEE SH. Oregonin inhibits inflammation and protects against barrier disruption in intestinal epithelial cells[J]. Int Immunopharmacol, 2018, 59: 134-140. DOI: 10.1016/j.intimp.2018.04.006.
    [34]
    SHAO C, TIAN G, HUANG Y, et al. Thymosin alpha-1-transformed bifidobacterium promotes T cell proliferation and maturation in mice by oral administration[J]. Int Immunopharmacol, 2013, 15(3): 646-653. DOI: 10.1016/j.intimp.2012.12.031.
    [35]
    SUGAHARA S, ICHIDA T, YAMAGIWA S, et al. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B[J]. Hepatol Res, 2002, 24(4): 346-354. DOI: 10.1016/s1386-6346(02)00145-6.
    [36]
    BOZZA S, GAZIANO R, BONIFAZI P, et al. Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo[J]. Int Immunol, 2007, 19(11): 1261-1270. DOI: 10.1093/intimm/dxm097.
    [37]
    YAO Q, DOAN LX, ZHANG R, et al. Thymosin-alpha1 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14+ monocytes[J]. Immunol Lett, 2007, 110(2): 110-120. DOI: 10.1016/j.imlet.2007.04.007.
    [38]
    GARACI E, PICA F, SERAFINO A, et al. Thymosin α1 and cancer: Action on immune effector and tumor target cells[J]. Ann N Y Acad Sci, 2012, 1269: 26-33. DOI: 10.1111/j.1749-6632.2012.06697.x.
    [39]
    NAYLOR PH, MUTCHNICK MG. Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach[J]. J Viral Hepat, 2018, 25(1): 4-9. DOI: 10.1111/jvh.12807.
    [40]
    PENG D, XING HY, LI C, et al. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: A systematic review and meta-analysis[J]. BMC Gastroenterol, 2020, 20(1): 348. DOI: 10.1186/s12876-020-01477-8.
    [41]
    WU J, ZHOU L, LIU J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): A multicenter, single-blind, randomized and controlled trial[J]. Crit Care, 2013, 17(1): R8. DOI: 10.1186/cc11932.
    [42]
    SARIN SK, CHOUDHURY A. Acute-on-chronic liver failure: terminology, mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(3): 131-149. DOI: 10.1038/nrgastro.2015.219.
    [43]
    YANG L, WU T, LI J, et al. Artificial liver treatment improves survival in patients with hepatitis B virus-related acute-on-chronic liver failure: A case-control matched analysis[J]. Hepatol Res, 2020, 50(6): 656-670. DOI: 10.1111/hepr.13497.
    [44]
    LARSEN FS, SCHMIDT LE, BERNSMEIER C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial[J]. J Hepatol, 2016, 64(1): 69-78. DOI: 10.1016/j.jhep.2015.08.018.
    [45]
    OCSKAY K, KANJO A, GEDE N, et al. Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: A systematic review and network meta-analysis[J]. Ann Intensive Care, 2021, 11(1): 10. DOI: 10.1186/s13613-020-00795-0.
    [46]
    KHAMRI W, ABELES RD, HOU TZ, et al. Increased expression of cytotoxic T-lymphocyte-associated protein 4 by T cells, induced by B7 in sera, reduces adaptive immunity in patients with acute liver failure[J]. Gastroenterology, 2017, 153(1): 263-276. e8. DOI: 10.1053/j.gastro.2017.03.023.
    [47]
    ZHANG Z, ZHAO YC, CHENG Y, et al. Hybrid bioartificial liver support in cynomolgus monkeys with D-galactosamine-induced acute liver failure[J]. World J Gastroenterol, 2014, 20(46): 17399-17406. DOI: 10.3748/wjg.v20.i46.17399.
    [48]
    BAÑARES R, NEVENS F, LARSEN FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial[J]. Hepatology, 2013, 57(3): 1153-1162. DOI: 10.1002/hep.26185.
    [49]
    KRIBBEN A, GERKEN G, HAAG S, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure[J]. Gastroenterology, 2012, 142(4): 782-789. e3. DOI: 10.1053/j.gastro.2011.12.056.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (567) PDF downloads(63) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return